JP2021091683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021091683A5 JP2021091683A5 JP2020202383A JP2020202383A JP2021091683A5 JP 2021091683 A5 JP2021091683 A5 JP 2021091683A5 JP 2020202383 A JP2020202383 A JP 2020202383A JP 2020202383 A JP2020202383 A JP 2020202383A JP 2021091683 A5 JP2021091683 A5 JP 2021091683A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- nash
- stroke
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 17
- 206010016654 Fibrosis Diseases 0.000 claims 13
- 230000001771 impaired effect Effects 0.000 claims 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 230000004761 fibrosis Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 201000001320 Atherosclerosis Diseases 0.000 claims 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 8
- 206010022489 Insulin Resistance Diseases 0.000 claims 8
- 208000037803 restenosis Diseases 0.000 claims 8
- 230000002792 vascular Effects 0.000 claims 8
- 208000006011 Stroke Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 208000010444 Acidosis Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 208000002177 Cataract Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 206010012335 Dependence Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 206010056465 Food craving Diseases 0.000 claims 4
- 208000003790 Foot Ulcer Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010022562 Intermittent claudication Diseases 0.000 claims 4
- 208000007976 Ketosis Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 208000035180 MODY Diseases 0.000 claims 4
- 208000002720 Malnutrition Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010027417 Metabolic acidosis Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 4
- 208000001280 Prediabetic State Diseases 0.000 claims 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 208000021017 Weight Gain Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 4
- 230000010014 adipocyte dysfunction Effects 0.000 claims 4
- 238000002399 angioplasty Methods 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 206010009887 colitis Diseases 0.000 claims 4
- 208000018631 connective tissue disease Diseases 0.000 claims 4
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000008694 endothelial dysfunction Effects 0.000 claims 4
- 208000004104 gestational diabetes Diseases 0.000 claims 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 230000004153 glucose metabolism Effects 0.000 claims 4
- 230000002440 hepatic effect Effects 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 4
- 201000008980 hyperinsulinism Diseases 0.000 claims 4
- 201000001881 impotence Diseases 0.000 claims 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 4
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 230000004140 ketosis Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 230000001071 malnutrition Effects 0.000 claims 4
- 235000000824 malnutrition Nutrition 0.000 claims 4
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 4
- 230000000291 postprandial effect Effects 0.000 claims 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 230000004584 weight gain Effects 0.000 claims 4
- 235000019786 weight gain Nutrition 0.000 claims 4
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000005240 left ventricle Anatomy 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946084P | 2019-12-10 | 2019-12-10 | |
| US62/946,084 | 2019-12-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021091683A JP2021091683A (ja) | 2021-06-17 |
| JP2021091683A5 true JP2021091683A5 (enExample) | 2023-08-10 |
Family
ID=73835650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202383A Withdrawn JP2021091683A (ja) | 2019-12-10 | 2020-12-07 | ２−（（４−（（Ｓ）−２−（５−クロロピリジン−２−イル）−２−メチルベンゾ［ｄ］［１，３］ジオキソール−４−イル）ピペリジン−１−イル）メチル）−１−（（（Ｓ）−オキセタン−２−イル）メチル）−１Ｈ−ベンゾ［ｄ］イミダゾール−６−カルボン酸の１，３−ジヒドロキシ−２−（ヒドロキシメチル）プロパン−２−アミン塩の固体形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230045419A1 (enExample) |
| EP (1) | EP4073028A1 (enExample) |
| JP (1) | JP2021091683A (enExample) |
| KR (1) | KR20220112811A (enExample) |
| CN (1) | CN115175893A (enExample) |
| AR (1) | AR120703A1 (enExample) |
| AU (1) | AU2020402177A1 (enExample) |
| BR (1) | BR112022010599A2 (enExample) |
| CA (1) | CA3163979A1 (enExample) |
| MX (1) | MX2022007105A (enExample) |
| TW (1) | TWI809334B (enExample) |
| WO (1) | WO2021116874A1 (enExample) |
| ZA (1) | ZA202207589B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US20220193063A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Metabolites of glp1r agonists |
| US12065434B2 (en) | 2020-12-15 | 2024-08-20 | Pfizer Inc. | Metabolites of GLP1R agonists |
| AU2022349020A1 (en) | 2021-09-27 | 2024-05-09 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| KR20230140540A (ko) * | 2022-03-25 | 2023-10-06 | 일동제약(주) | Glp-1 수용체 작용제 화합물의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| CN116217522B (zh) * | 2023-02-22 | 2025-06-24 | 广东莱佛士制药技术有限公司 | Glp-1受体激动剂关键中间体的手性纯化方法 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| CN118812522A (zh) * | 2023-04-21 | 2024-10-22 | 苏州闻泰医药科技有限公司 | 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| ES2602111T3 (es) | 2010-09-30 | 2017-02-17 | Pfizer Inc | Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CN108473469B (zh) | 2015-12-29 | 2020-11-03 | 辉瑞公司 | 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷 |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| WO2020234726A1 (en) * | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2020
- 2020-12-07 TW TW109143088A patent/TWI809334B/zh not_active IP Right Cessation
- 2020-12-07 US US17/782,478 patent/US20230045419A1/en not_active Abandoned
- 2020-12-07 CA CA3163979A patent/CA3163979A1/en active Pending
- 2020-12-07 EP EP20824663.7A patent/EP4073028A1/en not_active Withdrawn
- 2020-12-07 MX MX2022007105A patent/MX2022007105A/es unknown
- 2020-12-07 CN CN202080095964.2A patent/CN115175893A/zh active Pending
- 2020-12-07 AU AU2020402177A patent/AU2020402177A1/en not_active Abandoned
- 2020-12-07 BR BR112022010599A patent/BR112022010599A2/pt not_active Application Discontinuation
- 2020-12-07 JP JP2020202383A patent/JP2021091683A/ja not_active Withdrawn
- 2020-12-07 KR KR1020227023147A patent/KR20220112811A/ko not_active Withdrawn
- 2020-12-07 WO PCT/IB2020/061585 patent/WO2021116874A1/en not_active Ceased
- 2020-12-09 AR ARP200103424A patent/AR120703A1/es unknown
-
2022
- 2022-07-08 ZA ZA2022/07589A patent/ZA202207589B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021091683A5 (enExample) | ||
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| JPWO2020103815A5 (enExample) | ||
| WO2015200078A8 (en) | Fatty acids and their use in conjugation to biomolecules | |
| HRP20221437T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| NO20045557L (no) | Kombinasjon av en DPP IV inhibitor og en kardiovaskulaer forbindelse | |
| JP2015503539A5 (enExample) | ||
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2016510795A5 (enExample) | ||
| JP2007522176A5 (enExample) | ||
| JP2016529253A5 (enExample) | ||
| JP2018505859A5 (enExample) | ||
| EP2308868B1 (en) | Histone deacetylase inhibitors and uses thereof | |
| JP2019531320A5 (enExample) | ||
| JP2016523243A5 (enExample) | ||
| BRPI0416627A (pt) | combinação de compostos orgánicos | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| CN107108603A (zh) | 芒果苷‑6‑o‑小檗碱盐及其制备方法与用途 | |
| JP2011508775A5 (enExample) | ||
| TW202345815A (zh) | Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物 | |
| JPWO2022078352A5 (enExample) | ||
| CN114522147B (zh) | 卡谷氨酸固体制剂及其制备方法 | |
| IL318410A (en) | Polymorphic form of GLP-1R agonist, method of preparation thereof and use thereof | |
| RU2023112071A (ru) | ТВЕРДЫЕ ФОРМЫ СОЛИ 2-((4-((S)-2-(5-ХЛОРПИРИДИН-2-ил)-2-МЕТИЛБЕНЗО[d][1,3]ДИОКСОЛ-4-ИЛ)ПИПЕРЕДИН-1-ИЛ)МЕТИЛ)-1-(((S)-ОКСЕТАН-2-ИЛ)МЕТИЛ)-1H-БЕНЗО[d]ИМИДАЗОЛ-6-КАРБОНОВОЙ КИСЛОТЫ С 1,3-ДИГИДРОКСИ-2-(ГИДРОКСИМЕТИЛ)ПРОПАН-2-АМИНОМ | |
| CN108069980B (zh) | 银杏内酯k新型衍生物及其制备方法和用途 |